



IRON DEFICIENCY¹

If the body does not absorb iron each day, **iron stores can gradually run down.**As the body's stores are used up, iron deficiency occurs.¹














In New Zealand, **1 in 6 women** under 45 years may have some form of iron deficiency^{2*}

IRON DEPLETION, IRON DEFICIENCY, IRON DEFICIENCY ANAEMIA are the low iron status spectrums needing diagnosis and investigation³

IRON DEPLETION

Occurs when haemoglobin levels are normal, but your body only has a small amount of stored iron (ferritin < 15–30 μ g/L).¹ The patient is asymptomatic or mildly symptomatic.³

IRON DEFICIENCY

The state of too little iron in the body; low iron stores (ferritin < 15–30 µg/L) and change in haemotological parameters. The patient is asymptomatic or symptomatic. 3

IRON DEFICIENCY ANAEMIA

An advanced stage of iron depletion; anaemia due to iron deficiency.



^{*} Defined as serum ferritin < 20 micrograms/L.

ADULTS AT RISK OF DEVELOPING IRON DEFICIENCY^{1,3}








People on restricted diets, e.g. vegans or vegetarians, people with inadequate iron absorption, consumption of iron inhibitors and certain medicines, obesity

Elite athletes





WHY IS IT IMPORTANT TO KNOW

ABOUT IRON DEFICIENCY



1 in 6 New Zealand women have some form of iron deficiency²



Iron deficiency can affect quality of life⁴



All iron deficiency should have the **underlying cause investigated** to exclude serious undiagnosed conditions, e.g. gastrointestinal bleeding to name a few¹



If symptoms persist, refer your patient to their GP for further investigation



SIGNS & SYMPTOMS OF IRON DEFICIENCY

Iron deficiency can have a negative impact on the quality of life, such as reduced work performance and mental health.

SIGNS AND SYMPTOMS INCLUDE:1,*

- Fatigue
- Tiredness
- Irritability
- Dizziness/light-headedness
- Weakness

- Brittle nails
- Poor concentration
- Decreased work performance
- Impaired immunity

Iron deficiency should be suspected whenever there is a complaint of fatigue, particularly recent onset of fatigue in an at-risk patient.

* Symptoms are not exclusive to iron deficiency. Refer the patient to a GP for further investigation.





WHAT TO LOOK FOR

IN AN ORAL IRON SUPPLEMENT





Dosage meets the Therapeutic Guidelines

that recommend a minimum of at least 100 mg
of elemental iron per day to treat iron deficiency⁶

Contains an absorption aid, e.g. Vitamin C⁷

Modified release formula to help reduce the risk of gastric side effects^{8,9,10}





ferrograd® and ferrograd® C tablets

NZ'S #1 SELLING THERAPEUTIC ORAL IRON SUPPLEMENT RANGE¹¹

Dosage exceeds the MINIMUM AMOUNT of elemental iron recommended in the Therapeutic Guidelines⁶

Made with Gradumet technology, providing modified release iron¹² Contains lactose.

Once-daily dose



Contains 105 MILLIGRAMS ELEMENTAL IRON and 500 milligrams vitamin C.

Dosage exceeds the minimum amount of elemental iron recommended in the Therapeutic Guidelines.⁶

Vitamin C aids in the absorption of iron.⁷

Made with Gradumet technology, providing modified release iron¹² Contains no animal derived or sourced ingredients.

Once-daily dose




PHARMACY ONLY MEDICINE



SUMMARY



Iron deficiency is a common medical condition affecting 1 in 6 NZ women under 45 years²



It is recommended that therapy continues for **3-6 months** to replenish depleted iron stores⁶



There are many oral preparations containing iron available over-the-counter in New Zealand, but few contain **enough elemental iron to treat iron deficiency**¹¹



ferrograd® C tablets contain a therapeutic dose of iron and is part of NZ's #1 selling therapeutic oral iron supplement range¹¹



REFERENCES:

- **1.** Gastroenterological Society of Australia (GESA). Iron Deficiency Clinical Update. First Edition 2008. Updated October 2015; 1–13.
- **2.** Beck KL et al. Suboptimal iron status and associated dietary patterns and practices in premenopausal women living in Auckland, New Zealand. Eur J Nutr 2013; 52: 467–476.
- **3.** Pasricha S et al. Iron deficiency. Lancet 2021; 397: 33–48.
- **4.** Patterson AJ et al. Iron Deficiency general health and fatigue: Results from the Australian Longitudinal study in women's health. Quality of Life Research 2000: 9; 491-497.
- **5.** Iron polymaltose indication, New Zealand Maltofer Tablet Datasheet. [Accessed June 2021] Available at: https://www.medsafe.govt.nz/.
- **6.** Iron Deficiency. Overview of Iron Deficiency. Therapeutic Guidelines Limited. (eTG August 2020 Edition). Published March 2016. [Accessed 24 May 2021]. Available at: http://tgldcpd.tg.org.au/ViewTopic? Topicfile=irondeficiency&guidelineName=Gastrointestinal&topicNavigation+navigateTopic.
- **7.** Brise H & Hallberg L. Acta Med Scand 1962;171(Suppl 376): 51–87. 2013; 52: 467–476.
- 8. Webster JJ. Current Therapeutic Research 4(4) Apr 1962; 130–134.
- 9. Blair H & Blair CJ. Coll Gen Pract 1967 Jan; 13(1): 117–121.
- **10.** Morrison J et al. Med J Aust 1988; 1: 482–484.
- 11. IMS MAT unit Data October 2021.
- **12.** ferrograd® and ferrograd® C product labels.



MANDATORIES:



ferrograd® (dried ferrous sulfate 325 milligrams, equivalent to 105 milligrams elemental iron) ferrograd® C (dried ferrous sulfate 325 milligrams, equivalent to 105 milligrams elemental iron and vitamin C 500 milligrams). Pharmacy Only Medicine. Indications: For the prevention and treatment of tiredness and fatigue associated with iron deficiency. Contraindications: Hemochromatosis and hemosiderosis, intestinal diverticula or obstruction, repeated blood transfusions and concomitant parenteral Fe. Precautions: Establish nature and cause of anaemia. Children. Adverse Effects: GI upset, black stools. Dosage & Administration: One tablet daily as directed by physician. Tablets should be swallowed whole. Iron supplements should not be taken for more than 12 months without consulting a healthcare professional. ferrograd® is a fully funded medicine. ferrograd® C is an unfunded medicine. Your patient will need to pay for this medicine. ferrograd® is a Viatris trade mark. Copyright © 2020 Viatris Inc. Mylan NZ Ltd, Auckand. All rights reserved.

FER-2021-0005

TAPS2167RY-1208

